While the global vaccination effort to curb the spread of COVID-19 continues to ramp up worldwide, access to COVID-19 vaccines, particularly in low- and middle-income countries, remains staggeringly low. In fact, low- and middle-income countries received less than one percent of available doses.
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
In simple terms, risk is the possibility of something bad happening. It’s the uncertainty around the consequences of an activity with respect to something that we value.
USP’s recently released COVID-19 Vaccine Handling Toolkit is helping to fill critical operational efficiency gaps that practice settings have identified in vaccine administration.
Show 11 More